Thomas Hope, MD, is Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco and Chief of Nuclear Medicine at the San Francisco VA Medical Center.
Dr. Hope’s main research focus is on novel imaging agents and therapies, particularly in neuroendocrine tumors and prostate cancer. He led the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI program. Dr. Hope also leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors and PSMA Radioligand Therapy at UCSF.
An international leader in PET/MR research and the translation of new molecular imaging agents, Dr. Hope launched the highly successful PSMA prostate program at UCSF and championed the use of multiple new targeted therapies to treat patients with neuroendocrine and other tumors. He currently serves as principal investigator on grants from the NIH and the Prostate Cancer Foundation. Dr. Hope is the recipient of numerous honors in molecular imaging, including the Henkin Fellow and Marc Tetalman Memorial Award from the Society of Nuclear Medicine and Molecular Imaging, the Young Investigator Award from the Prostate Cancer Foundation, and the Wylie J. Dodds Research Award from the Society of Abdominal Radiology.
